ALTIMMUNE, INC. Noncash or Part Noncash Acquisition, Intangible Assets Acquired
ALTIMMUNE, INC. (ALT) reported Noncash or Part Noncash Acquisition, Intangible Assets Acquired of $5.76 thousand for the 6-month period ending 2018-06-30, per its 10-Q filed 2019-08-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1 · last filed 2019-08-13
- ALTIMMUNE, INC. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2018-06-30 was -$6.51K.
- ALTIMMUNE, INC. noncash or part noncash acquisition, intangible assets acquired for the quarter ending 2018-03-31 was $12.27K.
| Period end | Noncash or Part Noncash Acquisition, Intangible Assets Acquired 3 month | Noncash or Part Noncash Acquisition, Intangible Assets Acquired 6 month |
|---|---|---|
| 2018-06-30 | -$6.51K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $5.76K 10-Q · filed 2019-08-13 |
| 2018-03-31 | $12.27K 10-Q · filed 2019-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |